resiquimod
resiquimod: 5 clinical trials tracked.
resiquimod evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about resiquimod, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (5)
A Multicenter, Randomized, Double-Blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of BDB-001 Injection in Patients With ANCA-Associated Vasculitis
Primary endpoint: The proportion of patients achieving disease remission assessed by Birmingham Vasculitis Activity Score (BVAS)
A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis
Primary endpoint: The proportion of patients achieving disease complete remission or partial remission assessed by Birmingham Vasculitis Activity Score (BVAS)
A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment
Primary endpoint: Efficacy as measured by Objective Response Rate
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Atezolizumab in Subjects With Advanced Solid Tumors
Primary endpoint: Safety and Tolerability: incidence of adverse events and any dose limiting toxicity
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Primary endpoint: Safety and Tolerability: incidence of adverse events and any dose limiting toxicity